HAE International Community

ViroPharma Incorporated

Corporate Headquarters:ViroPharma Logo

730 Stockton Drive
Exton, PA 19341
United States of America

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products that address unmet medical needs. We focus on providing products to physician specialists that support patients with serious diseases for which there is an unmet medical need, including disease caused by C1 inhibitor deficiency. In everything we do, throughout our organization, we are committed to patient and physician needs, as we work to bring new products to markets with few, if any, therapeutic options. We are dedicated to transforming the promise of biotechnology into therapies that have the power to restore health and save lives.

C1-Inhibitor Concentrate - Trade Name Cinryze

Viropharma (Cinryze brand of C1 inhibitor) a C1 inhibitor concentrate product that is produced from US source plasma at Sanquin’s plant in Amsterdam, The Netherlands. Currently Cinryze is only sold in the US.

In Oct 2008, ViroPharma received FDA approval for Cinryze, the company's C1 inhibitor concentrate product, as an attack prevention therapy. The European brand of this product has an impressive safety record spanning three decades; and the version that will be sold in the US offers enhanced assurance by adding double nano filtration.

Approved by FDA for prophylactic treatment of hereditary angioedema in the US.